Is Bloom Energy Flying Under the Radar?
Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…
Sell
36
MAIA Quote, Financials, Valuation and Earnings
Last price:
$1.68
Seasonality move
:
-9.85%
Day range:
$1.74 - $1.90
52-week range:
$1.40 - $4.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
11.08x
Volume:
1.6M
Avg. volume:
539.9K
1-year change:
-51.37%
Market cap:
$54.8M
Revenue:
--
EPS (TTM):
-$0.79
Analysts' Opinion
-
Consensus RatingMAIA Biotechnology has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.14, MAIA Biotechnology has an estimated upside of 581.74% from its current price of $1.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.27 representing 100% downside risk from its current price of $1.78.
Fair Value
-
According to the consensus of 1 analyst, MAIA Biotechnology has 581.74% upside to fair value with a price target of $12.14 per share.
MAIA vs. S&P 500
-
Over the past 5 trading days, MAIA Biotechnology has underperformed the S&P 500 by -8.32% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MAIA Biotechnology does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MAIA Biotechnology has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MAIA Biotechnology reported revenues of --.
Earnings Growth
-
MAIA Biotechnology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MAIA Biotechnology reported earnings per share of -$0.16.
Enterprise value:
43.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.69x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$16.6M | -$19.8M | -$18.4M | -$3.9M | -$5.4M | |
| EBITDA | -$16.5M | -$19.6M | -$20.6M | -$3.9M | -$5.4M | |
| Diluted EPS | -$1.54 | -$1.58 | -$0.79 | -$0.46 | -$0.16 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $10.5M | $8.3M | $8.7M | $11.9M | |
| Total Assets | -- | $11.4M | $9.1M | $8.7M | $11.9M | |
| Current Liabilities | -- | $2.4M | $3.8M | $4.9M | $5.1M | |
| Total Liabilities | -- | $2.4M | $4M | $14.5M | $6.9M | |
| Total Equity | -- | $9M | $5.1M | -$5.8M | $4.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.6M | -$13.3M | -$16.3M | -$3.6M | -$4.2M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $9.9M | $14M | $18.9M | $4.7M | $5.5M | |
| Free Cash Flow | -$12.6M | -$13.3M | -$16.3M | -$3.6M | -$4.2M | |
MAIA
Sector
Market Cap
$54.8M
$35.2M
Price % of 52-Week High
41.98%
48.58%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-51.37%
-36.85%
Beta (5-Year)
--
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.82
200-day SMA
Sell
Level
$2.02
Bollinger Bands (100)
Buy
Level
1.59 - 1.95
Chaikin Money Flow
Sell
Level
-24.1M
20-day SMA
Sell
Level
$1.81
Relative Strength Index (RSI14)
Sell
Level
48.37
ADX Line
Buy
Level
22.15
Williams %R
Neutral
Level
-79.5699
50-day SMA
Sell
Level
$1.81
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
51.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 ‘-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
Stock Forecast FAQ
In the current month, MAIA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MAIA average analyst price target in the past 3 months is $12.14.
-
Where Will MAIA Biotechnology Stock Be In 1 Year?
According to analysts, the consensus estimate is that MAIA Biotechnology share price will rise to $12.14 per share over the next 12 months.
-
What Do Analysts Say About MAIA Biotechnology?
Analysts are divided on their view about MAIA Biotechnology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MAIA Biotechnology is a Sell and believe this share price will drop from its current level to $10.27.
-
What Is MAIA Biotechnology's Price Target?
The price target for MAIA Biotechnology over the next 1-year time period is forecast to be $12.14 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MAIA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MAIA Biotechnology is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of MAIA?
You can purchase shares of MAIA Biotechnology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MAIA Biotechnology shares.
-
What Is The MAIA Biotechnology Share Price Today?
MAIA Biotechnology was last trading at $1.68 per share. This represents the most recent stock quote for MAIA Biotechnology. Yesterday, MAIA Biotechnology closed at $1.78 per share.
-
How To Buy MAIA Biotechnology Stock Online?
In order to purchase MAIA Biotechnology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
80
SOC alert for Jul 18
Sable Offshore [SOC] is up 11.86% over the past day.
Buy
71
PGY alert for Jul 18
Pagaya Technologies [PGY] is up 5.56% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 0.31% over the past day.
